CytoSorbents
CytoSorbents is dedicated to advancing blood purification technology through innovative solutions that address critical health challenges. Their proprietary bead technology effectively removes harmful substances from the blood, providing healthcare professionals with powerful tools to improve patient outcomes in various medical conditions. The company is also focused on expanding its product offerings to include solutions for organ perfusion and antithrombotic removal. CytoSorb therapy is recognized for its ability to stabilize macro-hemodynamics, improve tissue perfusion, protect vital organs, and reduce bleeding complications, leading to enhanced patient recovery and high survival rates. CytoSorb is particularly effective in critical care settings, addressing systemic hyperinflammation and improving outcomes in patients with conditions such as septic shock and acute respiratory distress syndrome (ARDS). Additionally, CytoSorbents emphasizes the importance of training and education for healthcare professionals, ensuring they are equipped with the knowledge and skills to effectively utilize their technologies.
CytoSorbents
CytoSorbents Europe GmbH, Germany
What We Do
A blood purification therapy that removes excessive levels of cytokines, bilirubin, and myoglobin, helping to restore balance and prevent damage.
A standalone platform tailored to CytoSorb for hemoadsorption treatments, designed to retain specific molecules responsible for disease development directly from the blood.
An adsorption system designed for the dialysis of ex-vivo organ perfusion solutions, aimed at reducing inflammation during organ perfusion.
A specialized application of CytoSorb technology for veterinary use, aimed at improving health outcomes in pets during emergencies.
An investigational device designed to remove antithrombotic drugs from patients to reduce the risk of perioperative bleeding complications.
A development-stage filter designed to create 'universal plasma' by removing anti-A and anti-B antibodies, allowing plasma to be given off-the-shelf to anyone in need.
Infectious Diseases
Key People
Chief Medical Officer
Senior Medical Manager Cardiovascular
Vice President Medical Cardio-Vascular
Senior Manager Medical Information
Vice President Medical Critical Care
VP Direct Business Europe & Therapy Area Liver/Kidney
News & Updates
An event showcasing CytoSorbents' technology and solutions in blood purification.
CytoSorbents at the DIVI in Hamburg, Germany, featuring a campfire session on individualized patient treatment with CytoSorb therapy.
CytoSorbents at the 10th RB Congress 2024, 5 – 7, Dec 2024. Visit us at our booth!
CytoSorbents at the Critical Care Down Under 2024, 10 – 11 Dec, 2024. Visit us at our booth!
An online event discussing medical documentation and the criteria for the indication of hemoadsorption with CytoSorb.
An event focused on intensive care medicine and nursing, featuring discussions on the latest advancements in the field.
A conference on intensive care and emergency medicine, showcasing the latest research and technologies.
CytoSorb has been utilized in various clinical settings, including critical care, cardiovascular care, liver care, and kidney care, demonstrating efficacy in reducing inflammatory mediators and improving patient outcomes.
CytoSorb is approved in the EU and authorized in over 75 countries. It is not yet approved in the US or Canada for any indication outside of Emergency Use Authorization for COVID-19.
CytoSorb helps to restore the balance by removal of excessive levels of cytokines, stabilizing the patient’s hemodynamics, and improving outcomes in critical care settings.
CytoSorb has been shown to effectively and safely remove elevated levels of myoglobin, while additionally addressing any concomitant hyperinflammation, helping in the management of rhabdomyolysis.
CytoSorb provides liver toxin removal and immunomodulation, effectively reducing elevated levels of cytokines and bilirubin, thereby promoting hemodynamic stability and recovery of liver function.
CytoSorbents offers ongoing training and education in hemoadsorption technology, ensuring healthcare professionals are equipped with the knowledge and skills to effectively utilize their products.
A collection of testimonials from healthcare professionals around the world highlighting the effectiveness of CytoSorb in various critical care scenarios.
The CytoSorb Literature Database has just surpassed 1,000 entries – One thousand peer-reviewed publications, poster presentations from national and international conferences and case reports from many different hospitals worldwide.
Initial report of the International Safe and Timely Antithrombotic Removal (STAR) Registry focusing on intraoperative hemoadsorption for antithrombotic drug removal during cardiac surgery.
Rapid and effective elimination of myoglobin with CytoSorb® hemoadsorber in patients with severe rhabdomyolysis.
Impact of CytoSorb Hemoadsorption Therapy on Fluid Balance in Patients with Septic Shock.
Results of a single site study of 60 patients undergoing heart transplantation, randomized to receive CytoSorb or standard treatment.